featured
Cutaneous Immune-Related Adverse Events Are Associated With Increased Survival in Patients Treated With Anti-PD-1 and Anti-PD-L1 Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy
JAMA Dermatol 2022 Jan 12;[EPub Ahead of Print], K Tang, J Seo, BC Tiu, TK Le, V Pahalyants, NS Raval, PO Ugwu-Dike, L Zubiri, V Naranbhai, M Carrington, A Gusev, KL Reynolds, NR LeBoeuf, MM Asgari, SG Kwatra, YR SemenovFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.